The role of neurotransmitters in regulation of energy homeostasis and possibility of drug correction of its disturbances in obesity
https://doi.org/10.14341/omet201619-15
Abstract
In today's world the problem of obesity is discussed in the context of non-communicable diseases, leading to significant encumbrances on society. This article provides information about the basics of the regulation of energy balance and eating behavior. Particular attention is paid to the role of neurotransmitters, including serotonin, a metabolic disorder that is one of the suspected causes of eating disorders. Demonstrated experience in the use of sibutramine in the world, and in the Russian practice, taking into account the impact on the development of comorbid conditions and their complications.
About the Authors
Ivan I. Dedov
Endocrinology Research Centre
Russian Federation
MD, Ph.D, academician of the Russian Academy of Sciences, Director
Russian Federation
MD, Ph.D, academician of the Russian Academy of Sciences, Director
Ekaterina A. Troshina
Endocrinology Research Centre
Russian Federation
MD, Ph.D. Professor, Head of the Therapy Department with a group of obesity
Russian Federation
MD, Ph.D. Professor, Head of the Therapy Department with a group of obesity
Natalya V. Mazurina
Endocrinology Research Centre
Russian Federation
Ph.D.leading researcher at Therapy Department with a group of obesity
Russian Federation
Ph.D.leading researcher at Therapy Department with a group of obesity
Marina O. Galieva
Endocrinology Research Centre
Russian Federation
postgraduate student
Russian Federation
postgraduate student
Oksana V. Logvinova
Endocrinology Research Centre
Russian Federation
resident
Russian Federation
resident
References
1. Диагностика и лечение ожирения у взрослых. Рекомендации Российской ассоциации эндокринологов. Под редакцией И.И. Дедова. – Москва, 2010. [Diagnostika I lechenie ozhireniya u vzroslyh. Rekomendacii Rossijskoj Associacii Ehndokrinologov. Ed by Dedov I.I. Moscow; 2010 (In Russ.)]
2. Carnell S, Gibson C, Benson L, et al. Neuroimaging and obesity: current knowledge and future directions. Obes Rev. 2012;13(1):43-56. doi: 10.1111/j.1467-789X.2011.00927.x.
3. Кремнева Е.И., Суслин А.С., Говорин А.H., и др. фМРТ-картирование алиментарных зон головного мозга. Анналы клинической и экспериментальной неврологии. Том 9. №1 2015; 32-36. [Kremneva EI, Suslin AS, Govorin AN, et al. Mapping of the brain regions responsible for eating behavior regulation with functional MRI. Annals of clinical and experimental neurology. 2015;9(1): 32-36 (In Russ.)]
4. Ожирение. Под редакцией Дедова И.И., Мельниченко Г.А. / Москва: Медицинское информационное агентство, 2004. [Obesity. Ed by Dedov II, Melnichenko GA. Moscow: Medicinskoe informacionnoe agenstvo; 2004 (In Russ.)]
5. Yeo G, Heisler L. Unraveling the brain regulation of appetite: lessons from genetics. Nat Neurosci 2012; 15 (10): 1343–1349. doi: 10.1038/nn.3211.
6. Fry M, Hoyda T, Ferguson A. Making sense of it: roles of the sensory circumventricular organs in feeding and regulation of energy homeostasis. Exp Biol Med (Maywood) 2007; 232: 14–26.
7. Гайтон А.К., Холл Д.Э. Медицинская физиология. Москва: Логосфера, 2008.- 1296с. [Gayton AK, Kholl DE. Textbook of Medical Physiology. Moscow: Logosfera, 2008; 1296 (In Russ.)].
8. Guo J, Simmons W, Herscovitch P, et al. Striatal dopamine D2-like receptor correlation patterns with human obesity and opportunistic eating behavior. Mol Psychiatry. 2014;19 (10): 1078-84. doi: 10.1038/mp.2014.102
9. Van Strien T, Snoek H, Van der Zwaluw C, Engels R. Parental control and the dopamine D2 receptor gene (DRD2) interaction on emotional eating in adolescence. Appetite. 2010; 54 (2): 255-61. doi: 10.1016/j.appet.2009.11.006
10. Lam D, Garfield A, Marston O, et al. Brain serotonin system in the coordination of food intake and body weight. Pharmacol Biochem Behav 2010; 97 (1): 84–91. doi:10.1016/j.pbb.2010.09.003.
11. Best J, Nijhout H, Reed M. Serotonin synthesis, release and reuptake in terminals: a mathematical model. Theoretical Biology and Medical Modelling 2010; 7: 34. doi:10.1186/1742-4682-7-34
12. Heath MJ, Hen R. Serotonin receptors. Genetic insights into serotonin function. Curr Biol. 1995; 5: 997–999. doi: 10.1016/S0960-9822(95)00199-0
13. Garfielda A, Burkea L, Shawa J, et al. Distribution of cells responsive to 5-HT6 receptor antagonist-induced hypophagia. Behavioural Brain Research 2014; 266: 201–206. doi: 10.1016/j.bbr.2014.02.018
14. Wurtman R, Wurtman J. Brain serotonin, carbohydrate-craving, obesity and depression.
15. Obes Res. 1995; 3 (4): 477-480 doi: 10.1002/j.1550-8528.1995.tb00215.x
16. Satoskar RS, Bhandarkar SD, Rege NN. Pharmacology and Pharmacotherapeutics; 20th ed. Mumbai: Popular Prakashan; 2007.
17. Smith S, Weissman N, Anderson C, et al. Multicenter, placebo-controlled trial of lorcaserin for weight management. N Engl J Med. 2010; 363 (3): 245–256. doi: 10.1056/NEJMoa0909809
18. Chan E, He Y, Chui C, et al. Efficacy and safety of lorcaserin in obese adults: a meta-analysis of 1-year randomized controlled trials (RCTs) and narrative review on short-term RCTs. Obes Rev. 2013;14 (5): 383-92. doi: 10.1111/obr.12015.
19. Karam J, McFarlane S. Tackling obesity: new therapeutic agents for assisted weight loss. Diabetes Metab Syndr Obes. 2010; 3: 95–112
20. Rucker D, Padwal R, Li S, et al. Long term pharmacotherapy for obesity and overweight: updated meta-analysis. BMJ. 2007; 335 (7631): 1194–1199. doi:10.1136/bmj.39385.413113.25
21. Zhou YH, Ma XQ, Wu C, et al. Effect of anti-obesity drug on cardiovascular risk factors: a systematic review and meta-analysis of randomized controlled trials. PLoS One. 2012; 7(6): e39062. doi: 10.1371/journal.pone.0039062
22. James W, Caterson I, Coutinho W, et al. SCOUT Investigators Effect of sibutramine on cardiovascular outcomes in overweight and obese subjects. N Engl J Med. 2010; 363 (10): 905–917. doi: 10.1056/NEJMoa1003114
23. Seimon R., Espinoza D., Ivers L. et al. Changes in body weight and blood pressure: paradoxical outcome events in overweight and obese subjects with cardiovascular disease. Int J Obes. 2014;38(9): 1165-1171 doi: 10.1038/ijo.2014.2.
24. Caterson I, Finer N, Coutinho W, et al. Maintained intentional weight loss reduces cardiovascular outcomes: results from the Sibutramine Cardiovascular OUTcomes (SCOUT) trial. Diabetes, Obesity and Metabolism. 2012; 14 (6): 523-30. doi: 10.1111/j.1463-1326.2011.01554.x.
25. Pavlik V, Fajfrova J, Slovacek L, Drahokoupilova E. The role of sibutramine in weight reduction. Bratisl Lek Listy. 2013; 114 (3): 155-157.
26. Аметов А.С. Отчет о программе ВЕСНА. Эффективное лечение ожирения – путь борьбы с эпидемией Diabetus mellipidus. // Эффективная фармакотерапия. Спецвыпуск. - 2013. - С. 7-11. [Ametov AS. Otchet o programme VESNA. Effektivnoe lechenie ozhireniya – put borbyi s epidemiey Diabetus mellipidus. Effektivnaya farmakoterapiya. Special edition. 2013; 7-11. (In Russ.)].
27. Мельниченко Г.А., Романцова Т.И., Журавлева М.В.. Всероссийская программа безопасного снижения веса «ПримаВера». Итоги первого года проведения. Ожирение и метаболизм. 2014; 1(38): 62-67. [Melnichenko GA, Romantsova TI, Zhuravleva MV. Vserossiyskaya programma bezopasnogo snizheniya vesa «PrimaVera». Itogi pervogo goda provedeniya. Obesity and metabolism. 2014; 1(38): 62-67. (In Russ.)]. doi:10.14341/omet2014162-68
28. Трошина Е.А., Мазурина Н.В., Галиева М.О. Создание стратегий лечения ожирения и коморбидных заболеваний на основе наблюдательных программ: промежуточные результаты всероссийской наблюдательной программы ПримаВера. // Альманах клинической медицины. – 2015. – №S1. – С. 95-101. [Troshina EA, Mazurina NV, Galieva MO. Development of therapeutic strategies for obesity and comorbid disorders based on observational programs: interim results of the Russian observational program PrimaVera. Almanah klinicheskoj mediciny. 2015; (S1): 95-101 (In Russ.)].
29. Hayes JF, Bhaskaran K, Batterham R, Smeeth L, Douglas I. The effect of sibutramine prescribing in routine clinical practice on cardiovascular outcomes: a cohort study in the United Kingdom. Int J Obes.. 2015;39(9):1359-1364. doi:10.1038/ijo.2015.86.
30. Caterson I, Coutino V, Finer N et al. Early response to sibutramine in patients not meeting current label criteria: preliminary analysis of SCOUT lead-in period. Obesity (Silver Spring). 2010;18(5):987-94. doi: 10.1038/oby.2009.327.
Review
For citations:
Dedov I.I., Troshina E.A., Mazurina N.V., Galieva M.O., Logvinova O.V. The role of neurotransmitters in regulation of energy homeostasis and possibility of drug correction of its disturbances in obesity. Obesity and metabolism. 2016;13(1):9-15. (In Russ.) https://doi.org/10.14341/omet201619-15
Views:
12858
This work is licensed under a Creative Commons Attribution-NonCommercial-NoDerivatives 4.0 International License (CC BY-NC-ND 4.0).
Email this article 
